: Not available.

Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?” / Picardi, Marco; Vincenzi, Annamaria. - In: HAEMATOLOGICA. - ISSN 1592-8721. - (2026). [10.3324/haematol.2026.301044]

Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

Picardi, Marco;Vincenzi, Annamaria
2026

Abstract

: Not available.
2026
Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?” / Picardi, Marco; Vincenzi, Annamaria. - In: HAEMATOLOGICA. - ISSN 1592-8721. - (2026). [10.3324/haematol.2026.301044]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1049707
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact